🎓 Anthropic just filed for a $965B IPO.
They also just gave you free access to learn how to build with their technology.
Anthropic Academy — launched March 2026.
Free. No paywall. Just an email.
👉 https://t.co/3xsNUMqXmc
17 courses available right now:
→ Building with the Claude API — production deployments, real architecture
→ Claude Code 101 — AI-assisted development from scratch
→ Introduction to Subagents — autonomous AI workflows
→ MCP Servers — build your own Model Context Protocol servers in Python
→ Claude Cowork — desktop automation for non-developers
Also available:
Claude Certified Architect Foundations — official certification for solution architects building with Claude. Announced March 12, 2026.
The honest take:
The company going public at nearly $1 trillion is also giving away the knowledge to build on their platform for free.
That's not charity. That's a moat strategy.
The more developers who know Claude — the harder it is to switch to OpenAI or Gemini.
Smart. Very smart.
Not financial advice. Somebody had to say it. 🐥
#Anthropic #AnthropicAcademy #AI #ClaudeAPI #FreeCourses
🦵 $RGNT — The knee cartilage repair nobody knew existed. Until today.
Regentis Biomaterials exploded +136% today. Before you chase the spike — here's what's actually behind it.
The product: GelrinC®
→ Off-the-shelf hydrogel implant for knee cartilage repair
→ 10-minute single-step procedure
→ CE Mark approved in Europe ✅
→ 100% greater pain improvement vs standard microfracture
→ MRI-confirmed cartilage regeneration up to 4+ years
The market nobody has solved:
→ 470,000 annual knee cartilage repair cases in the U.S.
→ Zero approved off-the-shelf solution available today
→ $3 billion market. Wide open.
The catalyst pipeline:
→ Q3 2026: European surgeon training begins in Milan 🇮🇹
→ 2026: Commercial launch in Europe
→ 2026-2027: Phase III FDA trial completion (50%+ enrolled)
→ 2027: FDA submission
The CEO:
Ehud Geller, PhD — former President & CEO of Interpharm Laboratories, former EVP at Teva Group. Not a turnaround specialist. A pharma builder.
The honest caveat:
Today's +136% was pure momentum on low float — spike to $7.33 premarket, back to $3 by afternoon. Book value: $0.92 per share. Current price trades well above fundamentals.
But the technology pipeline is real. The market opportunity is real. And the catalysts are coming.
Watch the story, not just today's chart.
Not financial advice. Do your own research.
$RGNT 🦵
Somebody had to say it. 🐥
#RGNT #Biotech #RegenerativeMedicine #GelrinC #Orthopedics
🚨 $PAVS — This chart is the warning.
+449% this morning. Back to $5 by afternoon. Afterhours: $0.89.
The history nobody checked before buying:
→ All-time high: $123,785 (2019)
→ Reverse split 1-for-100
→ Reverse split 1-for-12
→ Nasdaq delisting notice December 2025
→ Market cap today: $986K
What happened today:
Someone bought at $22. The stock is now $0.89 afterhours.
That's not a correction. That's a trap that closed.
The chart shows everything. The spike. The exit. The retail left holding.
One rule: if a stock has done more than one reverse split — walk away. Every time.
Not financial advice. Somebody had to say it. 🐥
#PAVS #NasdaqTrap #ReverseSplit #StockWarning
Anthropic just filed for IPO.
Valuation: $965B. Revenue run rate: $47B annually.
Two years ago they were doing $1B.
I use their API every day to build. Here's what I see from the inside:
Claude Code is the product that changed everything. It hit $1B in annualized revenue 6 months after launch — one of the fastest growth curves in enterprise software history.
But the number that really gets my attention isn't that one.
Customers spending $1M+/year on Claude went from 500 to 1,000+ in under two months.
That's not adoption. That's dependency.
When a company puts $1M+/year into a tool, they don't switch easily. Anthropic isn't selling software — they're selling themselves as critical infrastructure.
Real risks before the IPO: brutal compute costs, active IP litigation, and OpenAI, Google and Meta burning capital to compete.
Worth $965B? That's for the market to decide.
Building something the enterprise world can no longer let go of? I see that every single day.
Not financial advice.
Source: Fortune, June 1 2026
Somebody had to say it. 🐥
🚀 $SpaceX IPO — Musk just broke the Wall Street rulebook.
Financial Times confirmed today: Elon Musk is reserving up to 25% of SpaceX's $75B float for retail investors.
Historically, retail gets 5-10% in large IPOs. This is 2-5x the norm.
How to access it — confirmed brokers:
→ Robinhood
→ SoFi
→ E*Trade
→ Schwab
→ Fidelity
Why Musk is doing this:
240 million followers on X. Starship launches watched by the world. He wants his community — not Wall Street — at the center of ownership from day one.
The honest caveat:
SpaceX itself added a risk disclosure warning that retail participation could drive volatile trading post-IPO.
The final allocation hasn't been set — it will depend on demand.
IPO date: June 12, 2026.
This is not a pump. This is the largest IPO in history opening its doors to ordinary investors for the first time.
Somebody had to say it. 🐥
Source: Financial Times, June 5, 2026.
Not financial advice. Do your own research.
#SpaceX #IPO #ElonMusk #Robinhood #Retail
📊 The market is red. But not all red is the same.
Today's sell-off is being misread by most retail investors.
What actually happened:
→ Broadcom dropped sharply — dragged the entire AI/chip sector with it
→ Nasdaq: -1.13%
→ Dow Jones: all-time high +1.73%
→ Russell 2000 (small caps): +1.45%
This is not panic. This is rotation.
Money didn't leave the market.
It moved — from AI/chips into industrials, healthcare, financials and small caps.
The evidence:
→ UnitedHealth +5%
→ JPMorgan +3%
→ Eli Lilly +4%
→ Walmart +1%
→ Meanwhile: NVDA -2.42%, AMD -5.27%, INTC -6.09%
Why it happened:
→ Jobs report came in stronger than expected
→ Strong jobs = Fed keeps rates higher for longer
→ Higher rates = pressure on high-multiple growth/AI stocks
→ Iran negotiations adding geopolitical uncertainty to oil prices
What it means:
The bull market didn't end today.
The leadership changed.
Knowing the difference between panic and rotation is how you avoid selling the wrong thing at the wrong time.
Not financial advice. Somebody had to say it. 🐥
#StockMarket #Nasdaq #Rotation #MacroAnalysis #Investing
💊 $VERU — Novo Nordisk just put skin in the game.
When the world's leading GLP-1 company signs a supply agreement AND negotiates first rights on your drug — that's not courtesy. That's conviction.
What happened — verified SEC 8-K filing, June 4, 2026:
→ Novo Nordisk signed a clinical supply agreement with Veru Inc.
→ Novo will supply Wegovy at no cost for Veru's Phase 2b PLATEAU trial
→ In exchange: first negotiation rights on any future enobosarm commercial deal
→ The study evaluates enobosarm + semaglutide in older adults with obesity
Why this matters:
Novo Nordisk doesn't give away Wegovy for free unless internal data already tells them something worth protecting.
The science behind it:
→ Enobosarm is an oral selective androgen receptor modulator
→ Phase 2b QUALITY data showed: greater fat loss during active reduction AND significantly prevented weight regain after semaglutide was discontinued
→ That last part — preventing rebound — is the holy grail of obesity treatment
What analysts say today:
→ Canaccord: Buy — target $25
→ Oppenheimer: Outperform — target $24
→ Current price: ~$4.30
Next catalyst: Earnings August 6, 2026
Not financial advice. Do your own research.
$VERU 💊
Somebody had to say it. 🐥
#VERU #NovoNordisk #GLP1 #Obesity #Biotech
🚨 $FOXX — Irvine, California. Not China. Same playbook.
Foxx Development Holdings. American company. American address. +175% today with zero verified catalyst.
This is the Nasdaq Pump Playbook — and it's no longer just a foreign problem.
The mechanics �� always the same:
→ Float under 2 million shares
→ No SEC filing explaining the move
→ No product launch. No contract. No earnings beat.
→ Stock spikes 100-500% in one session
→ Retail buys the top
→ Price returns to base within 48 hours
$FOXX today:
→ Float: 1.25 million shares — one of the smallest on Nasdaq
→ 10-Q filing delayed November 2025
→ Trading halted December 2025 for volatility
→ Moved from $2.23 to $6.14 with no news.
The rule:
Float under 2M + no SEC filing = red flag. Always. Regardless of where the company was founded.
If you can't find the catalyst in 60 seconds — you ARE the catalyst.
Not financial advice. Somebody had to say it. 🐥
#FOXX #Nasdaq #StockWarning #PumpAndDump #DueDiligence
🚨 The Chinese Nasdaq Playbook. A thread.
Every week, retail loses money to the same script. Here's how it works — with real examples from the last 30 days.
The pattern — every single time:
→ Chinese micro-cap lists on Nasdaq with inflated IPO price
→ Stock bleeds -90% over months while insiders hold
→ Sudden +100-500% spike with zero verified catalyst
→ Retail sees it on TradingView's top gainers
→ Retail buys the exit
→ Stock returns to base within 48-72 hours
The receipts — June 2026:
→ $BIYA — Baiya International. +200% spike. No news. Back to $1.60 same week.
→ $TOPP — Toppoint Holdings. +208% in one session. Zero catalyst. Faded same day.
→ $CGTL — Creative Global Technology. Promoted on Twitter. No SEC filing explaining the move.
→ $STAK — Oilfield equipment. +90% today. Afterhours: already back to $1.74.
→ $HKIT — Hitek Global. +460% — two reverse splits in 60 days. Class action lawsuit active.
Why this keeps happening:
→ Nasdaq rules were designed for U.S. companies
→ Chinese firms comply on paper — audits, filings, disclosures
→ But the playbook runs in the gaps: low float, coordinated orders, social media promotion
→ The HFCAA exists. Enforcement is slow. Pumps are fast.
How to protect yourself:
→ No SEC filing explaining the move? Don't touch it.
→ Prior 12-month chart shows -80% decline? That's the setup, not the opportunity.
→ Reverse split history? Walk away.
→ Spike with no named catalyst? Someone needed your money.
The uncomfortable truth:
Not all Chinese companies on Nasdaq are running this playbook.
But enough are that the pattern is now predictable.
Learn the script. Don't fund it.
Not financial advice. Somebody had to say it. 🐥
#Nasdaq #ChineseStocks #StockMarket #RetailInvestors #DueDiligence
⚡ $XOS — Electric trucks pivoted to AI power infrastructure. This one is real.
Xos just posted its best quarter since going public — then launched a product that changes its entire story.
Q1 2026 — Verified numbers:
→ Revenue: $11.2M — up 89.8% YoY
→ Gross margin: 38.6% — record high
→ Operating loss: nearly cut in half
→ Unit deliveries: more than tripled
→ 2026 guidance: reaffirmed
The new catalyst — Power Hub 2.5MWh:
→ Containerized energy storage — ships in a standard intermodal container
→ Deploys megawatt-scale power in days vs. 3-7 years for grid interconnection
→ Built for AI data centers and industrial sites where the grid can't reach
→ Same proven architecture as the Xos Hub mobile EV charging platform
→ Already demonstrated to U.S. Air Force at TEVCON 2026
The honest caveat:
→ Still losing money — balance sheet risk is real
→ +234% already happened — the easy money is gone
→ Insider sold shares in May before the announcement
The real question:
Can Xos convert Power Hub into scalable contracts with data center operators?
If yes — this is a different company than the market priced two weeks ago.
If no — $6 was the exit, not the entry.
Not financial advice. Do your own research.
$XOS ⚡
Somebody had to say it. 🐥
#EnergyStorage #AIInfrastructure #XOS #DataCenters
⚡ $LASE — Real technology. Real defense interest. Real risk.
Laser Photonics surged +160% today. Here's what actually happened — and what didn't.
What IS real:
→ Laser Shield Anti-Drone system selected as top submission by the U.S. Department of War under MEIA Vulcan Call for Solutions
→ Invited to exclusive one-on-one technical exchange with government engineers
→ $250K order from Johnson & Johnson for custom laser drilling in medical devices
→ Revenue 2025: $8.34M — up 144% year over year
→ Technology deployed in aviation, defense, space, semiconductors
What is NOT real yet:
→ The company itself clarified: this is a technical review, not a procurement order. No contract has been awarded. (Coinbase)
→ Nasdaq compliance notice active — late quarterly filing
→ Losses of $32.56M in 2025 on $8.34M revenue
The honest read:
The technology is legitimate. The government interest is real. The +160% move priced in a contract that doesn't exist yet.
If LASE converts the evaluation into a funded program — different story entirely.
If it doesn't — today's buyers are holding a very expensive hope.
Know what you own before you buy the headline.
Not financial advice. Somebody had to say it. 🐥
$LASE
#Defense #Drones #LASE #DueDiligence
🐱 $RCAT — Red Cat Holdings. This is what real drone defense looks like.
While others add "drone" to their name for a pump, Red Cat has been building the real thing.
The numbers:
→ Q1 2026 Revenue: +849% year over year
→ Gross margins: +64.8 percentage points YoY
→ Cash position: $167.9M — zero debt risk
→ Up 81.5% in 2026 already
The contracts — all verified:
→ Black Widow drones to Japan's Ministry of Defense — Ground Self-Defense Force
→ Initial order from NATO's NSPA procurement channel
→ New Asia-Pacific ally order confirmed
→ Blue Ops: uncrewed surface vessel weapons system in development
→ Annual General Meeting: June 18, 2026
The macro tailwind:
→ Pentagon budget: $961.6B for FY2026
→ Trump administration evaluating direct equity investments in domestic drone companies
→ NDAA-compliant — the only way to sell to the U.S. government
Analyst target: $20.66
Current price: $15.18
Japan. NATO. Pentagon. Real revenue. Real margins.
Not financial advice. Do your own research.
$RCAT 🐱
Somebody had to say it. 🐥
#Drones #Defense #RCAT #Pentagon #NATO
🚨 $QUCY — Know who's running this company before you buy.
Quantum Cyber is up +34% today. Before you chase it, here's what SEC filings show about its CEO.
David Elliot Lazar — The pattern:
→ CEO of Custodian Ventures LLC — specializes in "assisting distressed public companies through custodianship"
→ Simultaneously runs 10+ companies according to SEC filings
→ Based in Panama City, Panama
→ His fund: Activist Investing LLC — self-described "turnaround situations" in distressed Nasdaq & NYSE companies
His track record:
→ Mainz Biomed (the previous name of $QUCY) ✓
→ NovaBay Pharmaceuticals ✓
→ Kala Bio ✓
→ OpGen ✓
→ Indaptus Therapeutics ✓
→ Sow Good ✓
Every single one: distressed company, private placement, rebrand, price spike.
The $QUCY playbook:
Mainz Biomed (failing diagnostics) → renamed Quantum Cyber → added "quantum + AI + drones" narrative → stock pumped +628% in 5 days
The question nobody is asking:
Is there real quantum technology here — or is this another turnaround specialist running the same script on a new company?
SEC filings are public. The pattern is documented.
Not financial advice. Do your own research.
$QUCY 🚨
Somebody had to say it. 🐥
#QUCY #NasdaqWarning #StockAnalysis #DueDiligence
🛸 $QTEX Update — The thesis is no longer speculation.
Two weeks ago we posted about QTREX Quantum when it was at $2.36.
Today, two things happened simultaneously:
1. Fortune 500 Purchase Order — Confirmed
→ QTREX received a real purchase order from a U.S.-based Fortune 500 multinational
→ AME system delivery to one of the customer's international sites
→ "A unique capability that cannot be achieved through conventional technologies"
2. $10M Private Placement — Closed today
→ New fundamental institutional investor
→ Not retail. Not a pump. A fund that did due diligence and wrote a $10M check.
Where we are:
→ Entry point we shared: $2.36
→ Today: $3.80
→ Analyst target: $5.00
The CEO bought back the crown jewel of his own legacy from Nano Dimension.
A Fortune 500 just placed a real order.
An institution just committed $10M.
We don't know the name of the Fortune 500 yet.
When that drops — this is a different conversation.
Not financial advice. Do your own research.
$QTEX 🛸
Somebody had to say it. 🐥
#QuantumComputing #QTEX #AME #Fortune500
🚨 $HKIT — This is not a breakout. This is a trap.
Here's the full picture nobody is showing you:
The reverse split history:
→ April 2026: 50-for-1 reverse split
→ May 26, 2026: Second reverse split announced
→ Two consolidations in under 60 days
The legal situation:
→ Rosen Law Firm opened a securities class action investigation in March 2026
→ Trading was halted May 28 — "news pending"
The numbers:
→ All-time high: $5,969 (2023)
→ All-time low: $1.46 — reached YESTERDAY
→ Today: +460% with zero verified catalyst
What's actually happening:
Someone needed an exit. The stock was halted, a reverse split was announced, and today retail is buying the "breakout."
There is no breakout. There is no catalyst. There is a pattern.
Two reverse splits + class action + halt + sudden pump = the oldest playbook on Nasdaq.
Don't be the exit liquidity.
Not financial advice. Somebody had to say it. 🐥
#HKIT #NasdaqTrap #ReverseSplit #StockWarning
🛸 $ASTC — Astrotech Corporation. Two verified catalysts. Nobody was watching.
While everyone chased SpaceX hype, this 1984 Austin-based science company quietly delivered two real milestones this week.
Catalyst 1 — Verified:
→ TRACER 1000 received ECAC/EU G1 approval — the highest European standard for explosive trace detection at airports
→ Opens aviation security contracts across the EU and all ECAC-linked markets
→ Currently deployed in 34 locations across 16 countries
Catalyst 2 — Verified:
→ Board approved a new strategic initiative for lunar resource development
→ Focus: semiconductor manufacturing, advanced computing and quantum systems on the Moon
→ Tied to NASA's Artemis Program and Commercial Lunar Payload Services
The numbers:
→ 32 employees
→ $1M annual revenue
→ Market cap was $6M two weeks ago
The move:
→ $2.30 base → $54 today
→ +1,174% this week
High risk. Real catalysts. Not a Chinese pump — founded 1984, Nasdaq-listed, SEC-verified filings.
Not financial advice. Do your own research.
$ASTC
Somebody had to say it. 🐥
#SpaceTech #Defense #Nasdaq #ASTC
🔆 $PRFX — Two businesses. One small company. One big move.
PRF Technologies (formerly PainReform) is an Israeli micro-cap doing something unusual: building two real platforms simultaneously.
What they actually have:
Healthcare side:
→ PRF-110: extended-release post-surgical pain relief — reduces opioid dependency
→ OcuRing-K: FDA IND cleared for Phase II trial in cataract surgery (H2 2026)
AI/Energy side:
→ DeepSolar Predict: AI platform for real-time revenue optimization across solar, wind and battery storage assets
→ Built on NVIDIA Connect with proprietary micro-climate modeling
→ 71 MW SaaS agreement already signed
The honest numbers:
→ Market cap: $1.17M
→ Revenue: $17K (yes, seventeen thousand)
→ 7 employees
→ Interim CEO since February 2026
Today: +223% on DeepSolar commercial launch announcement
The reality check:
This is a nano-cap with real technology but minimal commercial traction yet. The FDA clearance and NVIDIA partnership are verified facts. The revenue is near zero.
High risk. Verified catalysts. Not financial advice.
$PRFX
Somebody had to say it. 🐥
#AI #Solar #Biotech #PRFX
🚁 $UMAC — This is what a real drone play looks like.
While everyone was watching SpaceX, the Pentagon quietly declared drone dominance a "presidential priority" in Trump's $1.5T defense budget for FY2027.
Unusual Machines is positioned at the center of it:
→ Trump Jr. sits on the board — the political connection is real
→ Partner Powerus selected for Phase II of the Pentagon's $1B Drone Dominance Program
→ Q1 2026: Revenue $8.1M — up 296% YoY. EPS beat estimates by 46%
→ $75M in strategic materials purchase orders already initiated
→ Army contract for 3,500 drone motors with scale-up to 20,000 in 2026
→ 100% NDAA-compliant — the only way to sell to the U.S. government
The Trump administration is negotiating direct equity investments in domestic drone companies. UMAC is named.
This stock is up 150% from its YTD low (Phantom) — and the Pentagon funding hasn't been confirmed yet.
When it is — this is a different conversation.
$UMAC $29.60 today. Afterhours: $32.75.
Not financial advice. Do your own research.
#Drones #Defense #UMAC #PentagonContracts
🚨 How to spot a Chinese pump on Nasdaq — a thread
Every week, a Chinese micro-cap with $4M revenue and no news suddenly spikes 80-200% in a single session.
Here's exactly what it looks like. And why you should never touch it.
The pattern:
→ Stock trades flat for months near $0.80–$1.50
→ Volume explodes 8-10x with zero news
→ Price spikes violently intraday ($1.52 → $3.49 same day)
→ Retail sees "+78%" and chases
→ Early buyers exit on that retail demand
→ Stock returns to $1.20 within 48 hours
The tells:
→ Chinese company listed on Nasdaq or NYSE American
→ Revenue under $10M with operating losses
→ Previous 12-month chart shows a straight line DOWN from $50-$100 highs
→ No SEC filing, no press release, no catalyst
→ Low float = a few large orders move the price dramatically
The rule:
If you can't find a press release explaining the move — it's not a move. It's a trap.
Real catalysts leave paper trails. Pumps don't.
Not financial advice. Somebody had to say it. 🐥
🛸 $QTEX — This just got very real.
QTREX Quantum just filed financials confirming the April acquisition of Nano Dimension's AME and Fabrica lines.
The same CEO who built Nano Dimension just bought back the crown jewel of his own legacy — and plugged it into quantum cryogenic infrastructure.
→ Advanced discussions with a Top-5 global quantum computing company
→ Real AME hardware. Real cryogenic interconnects.
→ $2B quantum commitment from the US government
→ Stock: $0.37 two weeks ago. $3.25 today.
This isn't narrative. This is execution.
$QTEX
Not financial advice. Do your own research.
#QuantumComputing #QTEX #AME #NanoDimension